Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for TG Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will earn $0.72 per share for the year. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

TGTX has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 7th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. increased their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Trading Down 2.4 %

Shares of TG Therapeutics stock opened at $29.14 on Wednesday. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market cap of $4.54 billion, a PE ratio of -291.37 and a beta of 2.24. The firm has a fifty day moving average price of $31.57 and a 200 day moving average price of $26.01.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.73 earnings per share.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,358 shares of company stock valued at $781,497 over the last 90 days. Corporate insiders own 10.50% of the company’s stock.

Institutional Trading of TG Therapeutics

Several large investors have recently bought and sold shares of TGTX. NBC Securities Inc. boosted its holdings in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Blue Trust Inc. boosted its stake in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares during the last quarter. ORG Wealth Partners LLC acquired a new position in TG Therapeutics during the third quarter worth $53,000. Values First Advisors Inc. purchased a new stake in TG Therapeutics in the 3rd quarter valued at $58,000. Finally, GAMMA Investing LLC raised its holdings in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 2,171 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.